Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on October 4, 2008
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyn102
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
38/11/762    most recent
hyn102v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Tahara, M.
Right arrow Articles by Sakata, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tahara, M.
Right arrow Articles by Sakata, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Multicenter Phase II Study of Cetuximab Plus Irinotecan in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin and Fluoropyrimidines

Makoto Tahara1, Kuniaki Shirao2, Narikazu Boku3, Kensei Yamaguchi4, Yoshito Komatsu5, Yoshitaka Inaba6, Tatsuhiro Arai7, Nobuyuki Mizunuma8, Taroh Satoh9, Hiroya Takiuchi10, Tomohiro Nishina11 and Yuh Sakata12

1 Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Chiba
2 Department of Medical Oncology, Faculty of Medicine, Oita University, Yufu, Oita
3 Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Nagaizumi, Shizuoka
4 Department of Gastroenterology, Saitama Cancer Center Hospital, Ina-machi, Saitama
5 Department of Gastroenterology, Hokkaido University School of Medicine, Sapporo
6 Department of Diagnostic and Interventional Radiology, Aichi Cancer Center Hospital, Nagoya, Aichi
7 Department of Medical Oncology, Tochigi Cancer Center Hospital, Utsunomiya, Tochigi
8 Department of Medical Oncology, Ariake Cancer Institute Hospital, Tokyo
9 Department of Medical Oncology, Kinki University School of Medicine, Osakasayama, Osaka
10 Department of Gastroenterology, Osaka Medical College, Takatsuki, Osaka
11 Department of Medical Oncology, National Shikoku Cancer Center, Matsuyama, Ehime
12 Misawa Municipal Hospital, Misawa, Aomori, Japan

For reprints and all correspondence: Makoto Tahara, Division of Digestive Endoscopy and Gastrointestinal Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, Chiba 277-8577, Japan. E-mail: matahara{at}east.ncc.go.jp

Received July 10, 2008; accepted September 1, 2008

Objective: Cetuximab is a chimeric IgG1 monoclonal antibody that specifically blocks the epidermal growth factor receptor. We evaluated the efficacy and safety of cetuximab in combination with irinotecan in patients with metastatic colorectal cancer (CRC) refractory to irinotecan, oxaliplatin and fluoropyrimidines.

Methods: Cetuximab was administered initially at a dose of 400 mg/m2 followed by weekly infusions at 250 mg/m2. Irinotecan was administered either weekly at a dose of 100 mg/m2 or every 2 weeks at 150 mg/m2.

Results: Between October 2005 and February 2006, 39 consecutive patients were enrolled. The response and disease control rates (complete or partial response, or stable disease) were 30.8% (95% CI, 17.0–47.6) and 64.1% (95% CI, 47.2–78.8), respectively. With a median follow-up of 14.4 months, median time to progression was 4.1 months (95% CI, 2.7–5.1) and median survival time was 8.8 months (95% CI, 5.9–12.8). Patients (5.1%) developed Grade 3 acne-like rash.

Conclusions: Combination therapy of cetuximab and irinotecan is effective and well-tolerated in patients with metastatic CRC refractory to irinotecan, oxaliplatin and fluoropyrimidines.

Key Words: cetuximab • irinotecan • colorectal cancer • multicenter phase II study


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.